<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28817628</article-id><article-id pub-id-type="pmc">5560713</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0183321</article-id><article-id pub-id-type="publisher-id">PONE-D-17-16506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Gastrointestinal Tumors</subject><subj-group><subject>Gastric Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Helicobacter Pylori</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Helicobacter Pylori</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Helicobacter</subject><subj-group><subject>Helicobacter Pylori</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Database Searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Trials</subject><subj-group><subject>Randomized Controlled Trials</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Research and Development</subject><subj-group><subject>Clinical Trials</subject><subj-group><subject>Randomized Controlled Trials</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Clinical Trials</subject><subj-group><subject>Randomized Controlled Trials</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Meta-Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (Mathematics)</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Meta-Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Endoscopy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Gastritis</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Effectiveness of <italic>Helicobacter pylori</italic> eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference</article-title><alt-title alt-title-type="running-head">Effectiveness of <italic>Helicobacter pylori</italic> eradication to prevent gastric cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3057-6284</contrib-id><name><surname>Seta</surname><given-names>Takeshi</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Yoshimitsu</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Noguchi</surname><given-names>Yoshinori</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shikata</surname><given-names>Satoru</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sakai</surname><given-names>Tatsuya</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sakai</surname><given-names>Kyoko</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamashita</surname><given-names>Yukitaka</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Takeo</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Division of General Internal Medicine, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Family Medicine, Mie Prefectural Ichishi Hospital, Tsu, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Internal Medicine, Kyoto Katsura Hospital, Kyoto, Japan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Laboratory Medicine, Suita Saiseikai Hospital, Suita, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Katoh</surname><given-names>Masaru</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>National Cancer Center, JAPAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>t-nakayama@umin.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>e0183321</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Seta et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Seta et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0183321.pdf"/><abstract><sec id="sec001"><title>Background</title><p><italic>Helicobacter pylori</italic> infection is strongly associated with gastric cancer occurrence. However, it is unclear whether eradication therapy reduces the risk of gastric cancer occurrence. We evaluated whether <italic>H</italic>. <italic>pylori</italic> eradication reduces the risk of primary gastric cancer by using both risk ratio (RR) and risk difference (RD).</p></sec><sec id="sec002"><title>Methods</title><p>Searches of PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials.gov, controlled-trials.com, UMIN-CTR, JMACCT-CTR, and JAPIC-CTI between January 1965 and March 2017, supplemented with manual screening. Randomized controlled trials (RCTs) in which eradication therapy were implemented for the interventional group but not for the control group, and assessed the subsequent occurrence of primary gastric cancer as the main outcome. Two authors independently reviewed articles and extracted data. Integrated results for all data were presented as RR and RD.</p></sec><sec id="sec003"><title>Results</title><p>Seven studies met inclusion criteria. The reductions in risk of primary gastric cancer occurrence in terms of overall RR and RD were 0.67 (95% CI: 0.48 to 0.95) and -0.00 ([95% CI: -0.01 to 0.00]; number needed to treat: 125.5 [95% CI: 70.0 to 800.9]), respectively.</p></sec><sec id="sec004"><title>Conclusions</title><p>The effectiveness of <italic>H</italic>. <italic>pylori</italic> eradication therapy in suppressing the occurrence of primary gastric cancer was significant and comparable to that of previous studies in terms of the estimated RR. However, the estimated RD was slight and not statistically significant.</p></sec></abstract><funding-group><funding-statement>This study was supported by a grant-in-aid from the Japan Primary Care Association in 2015.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="4"/><page-count count="18"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data are available from PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials.gov, controlled-trials.com, UMIN-CTR, JMACCT-CTR, and JAPIC-CTI.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data are available from PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials.gov, controlled-trials.com, UMIN-CTR, JMACCT-CTR, and JAPIC-CTI.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p><italic>Helicobacter pylori</italic> was designated a definite carcinogen of gastric cancer in 1994 by the International Agency for Research on Cancer (IARC) [<xref rid="pone.0183321.ref001" ref-type="bibr">1</xref>]. Infection of the gastric mucosa eventually leads to cancer via superficial gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia [<xref rid="pone.0183321.ref002" ref-type="bibr">2</xref>]. Take <italic>et al</italic>. confirmed reductions in gastric cancer occurrence in follow-up studies of patients with peptic ulcers who had received eradication therapy [<xref rid="pone.0183321.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0183321.ref004" ref-type="bibr">4</xref>]. Fukase <italic>et al</italic>. showed in a randomized controlled trial (RCT) that <italic>H</italic>. <italic>pylori</italic> eradication therapy following endoscopic treatment of early-stage gastric cancer reduced the occurrence of metachronous gastric cancer by approximately 30% [<xref rid="pone.0183321.ref005" ref-type="bibr">5</xref>].</p><p>Fuccio <italic>et al</italic>. conducted a meta-analysis of seven RCTs that had been published in 2009, and reported that <italic>H</italic>. <italic>pylori</italic> eradication significantly reduces primary gastric cancer by roughly 35% in patients with gastritis or precancerous lesions [<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>]. However, this analysis included an RCT, in which endoscopic resection of early-stage gastric cancer suppressed the occurrence of metachronous cancer [<xref rid="pone.0183321.ref005" ref-type="bibr">5</xref>], as well as a set of multiple articles for a single study [<xref rid="pone.0183321.ref007" ref-type="bibr">7</xref>]. Ford and Moayyedi re-examined these data when these studies were excluded, and found that although the effect size was comparable, the reduction was no longer significant [<xref rid="pone.0183321.ref008" ref-type="bibr">8</xref>]. Subsequently, Ford <italic>et al</italic>. conducted systematic reviews within Asia of gastritis or precancerous lesions triggered by <italic>H</italic>. <italic>pylori</italic> and demonstrated that gastric cancer occurrence may be prevented by eradication therapy, based on the results of six RCTs published in 2013 [<xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0183321.ref010" ref-type="bibr">10</xref>]. In 2016, Lee, <italic>et al</italic>. updated the systematic review and showed a similar result [<xref rid="pone.0183321.ref011" ref-type="bibr">11</xref>].</p><p>Risk ratio (RR), a synonym for relative risk, means the ratio of two risks, usually of exposed and not exposed [<xref rid="pone.0183321.ref012" ref-type="bibr">12</xref>]. An RR of &#x0003c;1 means the event is less likely to occur in the interventional group than in the control group. Risk difference (RD), a synonym for attributable risk, means the difference of two risk, usually risk in the exposed minus risk in the unexposed. When the probability of primary endpoint of intervention group and placebo group is low, it is sometimes replaced by a large number in terms of risk ratio despite being slightly expressed by risk difference. These four systematic reviews [<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0183321.ref011" ref-type="bibr">11</xref>] only used the risk ratio (RR) as an integrative index. In risk communication, the ratio index is concerned to exaggerate the effect size compared to the absolute value or difference index [<xref rid="pone.0183321.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0183321.ref014" ref-type="bibr">14</xref>]. In based on the absolute value is inevitable for evaluating the size of the problem and is also useful for the deployment of policies. Although it has been repeatedly and strongly recommended to combine the risk difference and the risk ratio [<xref rid="pone.0183321.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0183321.ref019" ref-type="bibr">19</xref>], it has been reported that the risk difference compared to the risk ratio is reported less [<xref rid="pone.0183321.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0183321.ref022" ref-type="bibr">22</xref>]. Especially in the issue of primary prevention, in general, the absolute risk is small and the effect size of the intervention shown with the risk ratio will give an exaggerated impression.</p><p>This study aimed to re-examine the significance of <italic>H</italic>. <italic>pylori</italic> eradication therapy in suppressing gastric cancer by expanding the period and range of the literature search and by showing effect sizes with RR and risk difference (RD).</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><p>This systematic review and meta-analysis followed the PRISMA guidelines [<xref rid="pone.0183321.ref023" ref-type="bibr">23</xref>].</p><sec id="sec007"><title>Literature search</title><p>We searched the literature for RCTs published between January 1965 and March 2017, using PubMed, EMBASE, Google scholar, and the Cochrane library as English literature databases. Considering the high prevalence of gastric cancer in Japan and the availability of Japanese research articles, we also searched the Japan Medical Abstracts Society database [<xref rid="pone.0183321.ref024" ref-type="bibr">24</xref>]. Search terms were as follows: <italic>Helicobacter pylori</italic>, gastric cancer, intestinal metaplasia, gastric atrophy, dysplasia, atrophic gastritis, and chronic gastritis (final search conducted in April 2017). Electronic search strategy for PubMed database was shown in <xref ref-type="table" rid="pone.0183321.t001">Table 1</xref>.</p><table-wrap id="pone.0183321.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.t001</object-id><label>Table 1</label><caption><title>Electronic search strategy for PubMed database.</title></caption><alternatives><graphic id="pone.0183321.t001g" xlink:href="pone.0183321.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Search (((((randomized controlled trial) OR (randomized controlled trials))) AND ((chronic gastritis) OR (gastritis) OR (atrophic gastritis) OR (dysplasia) OR (gastric atrophy) OR (gastric metaplasia) OR (intestinal metaplasia))) AND helicobacter pylori) AND gastric cancer Filters: Humans; English; Japanese</td></tr></tbody></table></alternatives></table-wrap><p>A search was also conducted for clinical trials that had been registered by March 2017, using the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) [<xref rid="pone.0183321.ref025" ref-type="bibr">25</xref>], metaRegister of Controlled Trials (mRCT) [<xref rid="pone.0183321.ref026" ref-type="bibr">26</xref>], ClinicalTrials.gov [<xref rid="pone.0183321.ref027" ref-type="bibr">27</xref>], controlled-trials.com [<xref rid="pone.0183321.ref028" ref-type="bibr">28</xref>], University Hospital Medical Information Network in Japan Clinical Trials Registry (UMIN-CTR) [<xref rid="pone.0183321.ref029" ref-type="bibr">29</xref>], Center for Clinical Trials, Japan Medical Association Clinical Trial Registry (JMACCT-CTR) [<xref rid="pone.0183321.ref030" ref-type="bibr">30</xref>], and Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC-CTI) [<xref rid="pone.0183321.ref031" ref-type="bibr">31</xref>] (final search conducted in April 2017). In addition, we searched for previous systematic reviews and meta-analyses on the same topic. After this, we read through all titles and abstracts of the following representative Japanese journals in gastroenterology: <italic>&#x0201c;I to Cho&#x0201d;</italic> (Stomach and Intestine, published by Igaku-Shoin Ltd., Tokyo), <italic>&#x0201c;Shokakinaishikyou&#x0201d;</italic> (Endoscopia Digestiva, published by Tokyo Igakusha Ltd., Tokyo), and <italic>&#x0201c;Rinsho Shokakinaika&#x0201d;</italic> (Clinical Gastroenterology, published by Nihon Medical Center Inc., Tokyo) (final search conducted in April 2017). We then read through the entire text of articles related to the present topic. In cases where the same study participants were observed for gastric cancer occurrence at different times, we used the research article with the longest follow-up period.</p><p>Finally, we checked for studies in which multiple articles resulted from a single study, wherein extended observations of the same research participants included in the initial phase of the study were reported after the observations from the initial study had been published. Specifically, we contacted corresponding authors via e-mail and asked whether a single study resulted in multiple articles [<xref rid="pone.0183321.ref032" ref-type="bibr">32</xref>]; we decided in advance that if there was no reply after one week, a reminder e-mail would be sent to the author, and that if there was still no reply, the follow-up would be discontinued.</p><p>We used the &#x0201c;PRISMA-2009-Checklist&#x0201d; to evaluate the quality of literature search and eligibility criteria for this systematic review and meta analysis in <xref ref-type="supplementary-material" rid="pone.0183321.s001">S1 Table</xref>.</p></sec><sec id="sec008"><title>Eligibility criteria</title><sec id="sec009"><title>Inclusion criteria</title><p>Inclusion criteria were as follows: an RCT of <italic>H</italic>. <italic>pylori</italic> eradication therapy, or a study in which the occurrence of primary gastric cancer was subsequently followed up; an interventional group involving eradication therapy; a control group given &#x0201c;a placebo,&#x0201d; &#x0201c;no treatment (observation),&#x0201d; &#x0201c;a supplement,&#x0201d; or &#x0201c;an antacid containing a proton pump inhibitor (PPI),&#x0201d; none of which eradicated <italic>H</italic>. <italic>pylori</italic>; published in either English or Japanese; evidence of <italic>H</italic>. <italic>pylori</italic> infection demonstrated by a biochemical, serological, bacteriological, or histological method; and absence of gastric cancer as determined in advance by upper gastrointestinal endoscopy. Inclusion did not depend on the presence or absence of symptoms during participation in the study.</p></sec><sec id="sec010"><title>Exclusion criteria</title><p>Exclusion criteria were as follows: administration of eradication therapy in the control group; eradication therapy prior to group allocation; studies in which gastric cancer occurrence was not measured; studies that tracked whether metachronous cancer occurred after endoscopic therapy (endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)) for primary cancer; animal studies; basic medical research; pathological research; reviews; and guidelines.</p></sec></sec><sec id="sec011"><title>Main outcome measure</title><p>We designated primary gastric cancer occurrence as the outcome, regardless of whether the measure was the primary or secondary outcome in each study.</p></sec><sec id="sec012"><title>Data extraction</title><p>Based on eligibility criteria, two authors (T.S. and T.N.) independently checked the titles and summaries of all articles, searched and determined which were appropriate for inclusion. The other co-authors checked every process, and any issues that arose were resolved by discussion. The entire text of included articles was read, and the following information was extracted: year of publication; publication format; protocol; number of participating facilities in each study; subject characteristics; study country; language of publication; presence or absence of upper gastrointestinal symptoms at study initiation; method of eradication therapy; type of treatment in the control group; whether or not secondary eradication therapy was performed; treatment period; method of assessing <italic>H</italic>. <italic>pylori</italic> infection; number of times successful eradication was confirmed; primary and secondary outcomes; description of changes in gastric mucosa following eradication therapy; mean age; whether or not a difference was observed between the interventional and control groups; number of subjects; gastric cancer occurrence; histological type of gastric cancer; site of gastric cancer; degree of gastric cancer progression; gastric histological features at study initiation; histological assessment using updated Sydney System scores before and after eradication therapy [<xref rid="pone.0183321.ref033" ref-type="bibr">33</xref>]; proportion of subjects showing either intestinal metaplasia or dysplasia; clearly defined rationale for specifying the follow-up period; follow-up period; <italic>H</italic>. <italic>pylori</italic> eradication rate; drop-out rate; mean time to cancer occurrence; and time between endoscopies. Atrophic gastritis, intestinal metaplasia, and dysplasia were defined as precancerous lesions. We also noted whether there were multiple articles for a single study. If differences arose regarding details of the extracted data, all authors continued discussions until a consensus was achieved.</p></sec><sec id="sec013"><title>Quality assessment for primary trials</title><p>The quality of primary trials was assessed as described by Jadad <italic>et al</italic> [<xref rid="pone.0183321.ref034" ref-type="bibr">34</xref>]. This method assesses whether the trial is randomized, the appropriateness of randomization if present, whether the trial is double-blinded, the appropriateness of double-blinding if present, and withdrawals/dropouts, using a score of 0 or 1 for each item. Total scores thus range from 0 to 5. A high quality trial in this meta-analysis was defined by a Jadad score of &#x02265;3 points. The GRADE system was used to evaluate the risk of bias of each trial used in this meta-analysis [<xref rid="pone.0183321.ref035" ref-type="bibr">35</xref>]. An RCT was considered high quality if three or more of the six domains for assessing risk of bias were adequate. Ultimately, the quality of a study was determined by either the Jadad score or risk of bias.</p></sec><sec id="sec014"><title>Statistical analysis</title><p>In four previous meta-analyses [<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0183321.ref011" ref-type="bibr">11</xref>], the pooled RR was used as the main index. Because this index tends to overestimate the effect, we first used the pooled RD and then the pooled RR, after which the results were presented together. The RD was calculated as risk in the interventional group <italic>minus</italic> that in the control group. The RD described the absolute change in risk that was attributable to the intervention. In other words, if the intervention had an identical effect to the control, RD would be 0. If it reduced the risk, the risk difference would be less than 0; if it increased the risk, the RD would be bigger than 0. The RD ranged from -1 to 1. A &#x0201c;+&#x0201d; sign indicated that treatment was favored, while a &#x0201c;-&#x0201d; sign indicated that the control was favored. Afterwards, the weighted pooled estimates were calculated for binary data. A fixed-effect model weighted by the Mantel-Haenszel (M-H) method was used to pool RD [<xref rid="pone.0183321.ref036" ref-type="bibr">36</xref>], followed by a test of homogeneity. Homogeneity among trials was assessed using the I<sup>2</sup> test [<xref rid="pone.0183321.ref037" ref-type="bibr">37</xref>]. If the hypothesis of homogeneity was rejected, a random-effect model using the DerSimonian-Laird method was employed [<xref rid="pone.0183321.ref038" ref-type="bibr">38</xref>]. The potential for publication bias was examined by the funnel plot method [<xref rid="pone.0183321.ref039" ref-type="bibr">39</xref>], and the statistical significance of differences was evaluated in accordance with the methods of Begg or Egger [<xref rid="pone.0183321.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0183321.ref041" ref-type="bibr">41</xref>]. Given the observed risk difference, the number of patients that need to be treated (NNT) to prevent one adverse effect was also used as a measure of treatment effect; computationally speaking, NNT = 1/RD. Furthermore, the impact of eradication therapy, compared with placebo or no treatment, was expressed as a relative risk of occurrence of gastric cancer with 95% confidence intervals (CIs). All statistical analyses were performed with STATA statistical software version 14 [<xref rid="pone.0183321.ref042" ref-type="bibr">42</xref>]. Results are expressed as means and 95% CIs, unless indicated otherwise. P values &#x0003c; 0.05 were considered statistically significant. In addition, in order to evaluate visually whether the suppressive effect of eradication therapy on gastric cancer tends to change with time, we plotted the RD on the y-axis against the mean follow-up period for the interventional and control groups of each study on the x-axis, and fit a simple linear regression line based on the least squares method.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>Search results</title><p>We screened 3383 studies through database searches and by reading through publications. Of these, we excluded 3270 studies and evaluated 113 in detail, and were ultimately left with seven studies (<xref ref-type="fig" rid="pone.0183321.g001">Fig 1</xref>) [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. An RCT by Wong <italic>et al</italic>. compared four groups including a placebo group [<xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>]. Of these, the two groups that met the inclusion criteria and were thus extracted for this study included one for which treatment intervention was a typical eradication therapy, and placebo administration for the other. Of the 106 studies excluded, we confirmed three article sets that involved multiple articles for a single study, in which the subjects and study background were identical but the study period differed. The studies by Zhou <italic>et al</italic>.[<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], Mera <italic>et al</italic>.[<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], and Ma <italic>et al</italic>.[<xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>] were the long-term versions of those by Leung <italic>et al</italic>.[<xref rid="pone.0183321.ref007" ref-type="bibr">7</xref>], Correa <italic>et al</italic>.[<xref rid="pone.0183321.ref050" ref-type="bibr">50</xref>], and You <italic>et al</italic>. [<xref rid="pone.0183321.ref051" ref-type="bibr">51</xref>], respectively. Prior to their final report [<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], Zhou <italic>et al</italic>. had also published a summarized version [<xref rid="pone.0183321.ref052" ref-type="bibr">52</xref>]. In accordance with the methodology described above, we excluded short-term studies with the same background and ultimately included their long-term counterparts (each published after the short-term study). Although the study by Miehke <italic>et al</italic>.[<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>] was not included in previous four meta-analyses [<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0183321.ref011" ref-type="bibr">11</xref>], we included it here as it met our inclusion criteria. None of the RCTs in the Japan Medical Abstracts Society or the three gastrointestinal medical journals satisfied the inclusion criteria. The article by Saito <italic>et al</italic>. was an abstract published as a poster at an academic conference (Digestive Disease Week, DDW 2005) [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>]. Because the subsequent clinical study was not presented as an article, only the conference abstract was used. The research results were first published in Japanese; we did not find any article that later reported the same results in English.</p><fig id="pone.0183321.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.g001</object-id><label>Fig 1</label><caption><title>Flow of randomized controlled trials through the process of retrieval and inclusion in the meta-analysis comparing eradication treatment for Helicobacter pylori infection.</title><p>RCT, Randomized controlled trial.</p></caption><graphic xlink:href="pone.0183321.g001"/></fig></sec><sec id="sec017"><title>Study characteristics</title><p>Characteristics of all seven studies included in the final analysis [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>] are summarized in <xref ref-type="table" rid="pone.0183321.t002">Table 2</xref>. An intention-to-treat (ITT) analysis had been carried out in all of the studies, which were all published in English. Five of the seven studies were multicenter studies [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. Subjects were normal healthy individuals in four studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>] and unspecified in three [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]; none of the studies clearly stated that the subjects were patients. Upper abdominal symptoms during the study were absent in three studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>] and unspecified in four [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. The countries participating in the studies were China in four studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]; Japan in one [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>]; Columbia in one [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], and Austria, Czech Republic, and Germany in a jointly reported study [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>]. Treatment details were as follows:</p><table-wrap id="pone.0183321.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.t002</object-id><label>Table 2</label><caption><title>Characteristics of primary trials.</title></caption><alternatives><graphic id="pone.0183321.t002g" xlink:href="pone.0183321.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Author</th><th align="center" rowspan="2" colspan="1">Reference</th><th align="center" rowspan="2" colspan="1">Year</th><th align="center" rowspan="2" colspan="1">Format</th><th align="center" rowspan="2" colspan="1">Setting</th><th align="center" colspan="2" rowspan="1">Participants' background</th><th align="center" rowspan="2" colspan="1">Country</th><th align="center" colspan="3" rowspan="1">Treatment of</th><th align="center" rowspan="2" colspan="1">Method of assessing <italic>Helicobacter pylori</italic> infection</th><th align="center" colspan="2" rowspan="1">Outcome</th><th align="center" colspan="2" rowspan="1">Mean age of</th><th align="center" colspan="2" rowspan="1">Participants in the initial allocation</th></tr><tr><th align="center" rowspan="1" colspan="1">Hospital</th><th align="center" rowspan="1" colspan="1">Participants</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">Duration (days)</th><th align="center" rowspan="1" colspan="1">Primary</th><th align="center" rowspan="1" colspan="1">Secondary</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th></tr><tr><th align="center" rowspan="1" colspan="1">Miehlke S</th><th align="center" rowspan="1" colspan="1">43</th><th align="center" rowspan="1" colspan="1">2001</th><th align="center" rowspan="1" colspan="1">Full</th><th align="center" rowspan="1" colspan="1">Multicenters</th><th align="center" rowspan="1" colspan="1">University and general hospitals</th><th align="center" rowspan="1" colspan="1">Unclear</th><th align="center" rowspan="1" colspan="1">Austria, Czech Republic, and Germany</th><th align="center" rowspan="1" colspan="1">Omeprazole, 20mg; clarithromycin, 500mg; and amoxicillin, 1000mg, all twice daily</th><th align="center" rowspan="1" colspan="1">PPI</th><th align="center" rowspan="1" colspan="1">7</th><th align="center" rowspan="1" colspan="1">Histology <sup>13</sup>C-urea breath test</th><th align="center" rowspan="1" colspan="1">Incidence of gastric cancer</th><th align="center" rowspan="1" colspan="1">None</th><th align="center" rowspan="1" colspan="1">Unclear</th><th align="center" rowspan="1" colspan="1">Unclear</th><th align="center" rowspan="1" colspan="1">86</th><th align="center" rowspan="1" colspan="1">81</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Wong BCY</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">Full</td><td align="center" rowspan="1" colspan="1">Multicenters</td><td align="center" rowspan="1" colspan="1">Public health bureau</td><td align="center" rowspan="1" colspan="1">Good health</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">Omeprazole, 20mg; metronidazole, 400mg; and amoxicillin, 750mg, all twice daily</td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1"><sup>13</sup>C-urea breath test</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">42.0</td><td align="center" rowspan="1" colspan="1">42.0</td><td align="center" rowspan="1" colspan="1">817</td><td align="center" rowspan="1" colspan="1">813</td></tr><tr><td align="center" rowspan="1" colspan="1">Mera R</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Full</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Public health bureau</td><td align="center" rowspan="1" colspan="1">Good health</td><td align="center" rowspan="1" colspan="1">Colombia</td><td align="center" rowspan="1" colspan="1">Amoxicillin; metronidazole; and bismuth subsalicylate</td><td align="center" rowspan="1" colspan="1">Supplement</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">Histology</td><td align="center" rowspan="1" colspan="1">Mucosal healing</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">394</td><td align="center" rowspan="1" colspan="1">401</td></tr><tr><td align="center" rowspan="1" colspan="1">Saito D</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Abstract</td><td align="center" rowspan="1" colspan="1">Multicenters</td><td align="center" rowspan="1" colspan="1">University and general hospitals</td><td align="center" rowspan="1" colspan="1">Good health</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">Lansoprazole, 30mg; clarithromycin, 200mg; and amoxicillin, 750mg, all twice daily</td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Mucosal healing</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">379</td><td align="center" rowspan="1" colspan="1">313</td></tr><tr><td align="center" rowspan="1" colspan="1">Ma JL</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">Full</td><td align="center" rowspan="1" colspan="1">Multicenters</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">Lansoprazole, 30mg; clarithromycin, 200mg; and amoxicillin, 750mg, all twice daily</td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"><sup>13</sup>C-urea breath test Serum antibody</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">47.0</td><td align="center" rowspan="1" colspan="1">47.0</td><td align="center" rowspan="1" colspan="1">1130</td><td align="center" rowspan="1" colspan="1">1128</td></tr><tr><td align="center" rowspan="1" colspan="1">Wong BCY</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">Full</td><td align="center" rowspan="1" colspan="1">Multicenters</td><td align="center" rowspan="1" colspan="1">University</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">Omeprazole, 20mg; clarithromycin, 500mg; and amoxicillin, 1000mg, all twice daily</td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"><sup>13</sup>C-urea breath test</td><td align="center" rowspan="1" colspan="1">Mucosal healing</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">53.0</td><td align="center" rowspan="1" colspan="1">52.9</td><td align="center" rowspan="1" colspan="1">255</td><td align="center" rowspan="1" colspan="1">258</td></tr><tr><td align="center" rowspan="1" colspan="1">Zhou LY</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Full</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Public health bureau</td><td align="center" rowspan="1" colspan="1">Good health</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">Omeprazole, 20mg; clarithromycin, 500mg; and amoxicillin, 1000mg, all twice daily</td><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"><sup>13</sup>C-urea breath test</td><td align="center" rowspan="1" colspan="1">Mucosal healing</td><td align="center" rowspan="1" colspan="1">Incidence of gastric cancer</td><td align="center" rowspan="1" colspan="1">62.1</td><td align="center" rowspan="1" colspan="1">62.2</td><td align="center" rowspan="1" colspan="1">276</td><td align="center" rowspan="1" colspan="1">276</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" colspan="10" rowspan="1">Patients with gastric cancer</th><th align="center" colspan="2" rowspan="2">Follow up (year)</th><th align="center" colspan="2" rowspan="2">Patients lost to follow-up (%)</th><th align="center" rowspan="3" colspan="1">Method of the contact to the correspondance author</th><th align="center" rowspan="3" colspan="1">Existence of the reply to the question to the correspondance author</th><th align="center" colspan="2" rowspan="2">Contents of the reply</th><th align="center" rowspan="3" colspan="1">Reaction of the remind mail</th></tr><tr><th align="center" colspan="5" rowspan="1">Intervention group</th><th align="center" colspan="5" rowspan="1">Control group</th></tr><tr><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Intestine type</th><th align="center" rowspan="1" colspan="1">Gastric type</th><th align="center" rowspan="1" colspan="1">Cardic cancer</th><th align="center" rowspan="1" colspan="1">Non-cardic cancer</th><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Intestine type</th><th align="center" rowspan="1" colspan="1">Gastric type</th><th align="center" rowspan="1" colspan="1">Cardic cancer</th><th align="center" rowspan="1" colspan="1">Non-cardic cancer</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">Intervention group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">Redundant data</th><th align="center" rowspan="1" colspan="1">Unpublicated data</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">12.0</td><td align="center" rowspan="1" colspan="1">12.0</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">Connection was impossible</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">&#x02267;4</td><td align="center" rowspan="1" colspan="1">&#x02267;4</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Adress was unknown</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">14.7</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">8.6</td><td align="center" rowspan="1" colspan="1">9.3</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">E-mail</td><td align="center" rowspan="1" colspan="1">Connection was impossible</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>PPI, Proton pump inhibitor</p></fn></table-wrap-foot></table-wrap><p>Treatment in the intervention group was PCA (PPI + clarithromycin + amoxicillin) in five studies [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], BMA (bismuth + metronidazole + amoxicillin) in one [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], and PMA (PPI + metronidazole + amoxicillin) in one [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>]. Treatment in the control group was placebo in four studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], a supplement in one [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], no treatment in one [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>], and PPI in one [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>]. With the exception of one study [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], none of the studies had performed secondary <italic>H</italic>. <italic>pylori</italic> eradication therapy. The method for assessing <italic>H</italic>. <italic>pylori</italic> infection was the <sup>13</sup>C-Urea breath test in five studies [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], histology in two [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>], serum antibodies in one [<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], and unspecified in one [<xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>]. The number of times the effectiveness of <italic>H</italic>. <italic>pylori</italic> eradication was confirmed was only once in five studies [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], four times in one (by a breath test at the time of each endoscopy) [<xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>], and unspecified in one [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>].</p><p>In terms of outcome evaluation, gastric cancer occurrence had been designated as the primary outcome measure in three studies [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], while a secondary outcome measure was specified in four [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>&#x02013;<xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>]. In an upper gastrointestinal endoscopic examination following eradication therapy, one study [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>] found significant improvement of the gastric mucosa whereas three found no significant improvement [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>&#x02013;<xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>]; the other three did not assess this parameter [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>].</p><p>The total numbers of subjects for the interventional and control groups were 3337 and 3270, respectively, with a mean age of 51.0 years for both groups. Mean follow-up periods for the interventional and control groups were 7.8 and 6.7 years, respectively; the rationale for the follow-up period was not indicated in any study. Two studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>] reported the time to cancer onset following eradication therapy, and indicated mean times of 3.9 and 2.3 years for the interventional and control groups, respectively.</p><p>Histological assessment, using the updated Sydney System score before and after eradication therapy, was not possible for any of the studies. Endoscopy was performed annually in one study [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>] or following a fixed non-annual schedule in four studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>]; the schedule was unspecified in two studies [<xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>].</p><p>We sent e-mail inquiries to six of the eight corresponding authors [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>] whose addresses were listed, asking if multiple articles with redundant data had been published. E-mails sent to the listed addresses for two of these six authors did not reach their destinations [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. None of the remaining four authors replied within the first week; therefore, we sent a reminder to all of these authors [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. Because we received no replies even after another week, we conducted no further follow-ups.</p></sec><sec id="sec018"><title>Study quality</title><p>We first evaluated the quality of the seven RCTs in <xref ref-type="table" rid="pone.0183321.t003">Table 3</xref>. The median Jadad score was 3.0 (range: 1&#x02013;5). The primary outcome measure was described in the methodology of every study. Sample size had been specified in advance in three studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. The funding source was public in four studies [<xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>] and unspecified in three [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>]. None of the studies mentioned whether there were any conflicts of interest. In addition, although one study indicated that drugs were actually provided, six lacked such description [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>].</p><table-wrap id="pone.0183321.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.t003</object-id><label>Table 3</label><caption><title>Evidence quality of each RCT used.</title></caption><alternatives><graphic id="pone.0183321.t003g" xlink:href="pone.0183321.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Author</th><th align="center" rowspan="2" colspan="1">Reference</th><th align="center" colspan="3" rowspan="1">Description of</th><th align="center" colspan="2" rowspan="1">Description of grant</th><th align="center" colspan="6" rowspan="1">Limitations (Risk of bias) for each RCT</th><th align="center" colspan="6" rowspan="1">Jadad score</th><th align="center" rowspan="2" colspan="1">Quality of study</th></tr><tr><th align="center" rowspan="1" colspan="1">Main outcome in methods</th><th align="center" rowspan="1" colspan="1">Basis of sample size calculation in methods</th><th align="center" rowspan="1" colspan="1">Fund</th><th align="center" rowspan="1" colspan="1">Fund was supplied by sponsor company</th><th align="center" rowspan="1" colspan="1">Medicine was supplied by sponsor company</th><th align="center" rowspan="1" colspan="1">Allocation concealment</th><th align="center" rowspan="1" colspan="1">Adequate sequence generation</th><th align="center" rowspan="1" colspan="1">Blinding</th><th align="center" rowspan="1" colspan="1">Incomplete outcome data addressed</th><th align="center" rowspan="1" colspan="1">Free of elective outcome reporting</th><th align="center" rowspan="1" colspan="1">Free of other bias</th><th align="center" rowspan="1" colspan="1">Randomization</th><th align="center" rowspan="1" colspan="1">Appropriateness of randomization</th><th align="center" rowspan="1" colspan="1">Double blind</th><th align="center" rowspan="1" colspan="1">Appropriateness of double blind</th><th align="center" rowspan="1" colspan="1">Dropout</th><th align="center" rowspan="1" colspan="1">Sum</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Miehlke S</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">High</td></tr><tr><td align="center" rowspan="1" colspan="1">Wong BCY</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Public</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">High</td></tr><tr><td align="center" rowspan="1" colspan="1">Mera R</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Public</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" rowspan="1" colspan="1">Saito D</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" rowspan="1" colspan="1">Ma JL</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Public</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">High</td></tr><tr><td align="center" rowspan="1" colspan="1">Wong BCY</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Public</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">High</td></tr><tr><td align="center" rowspan="1" colspan="1">Zhou LY</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Unclear</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">High</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>RCT, Randomized controlled trial</p></fn></table-wrap-foot></table-wrap><p>Regarding the risk of bias for each RCT, three studies mentioned <italic>allocation concealment</italic> [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref047" ref-type="bibr">47</xref>], all noted <italic>adequate sequence generation</italic>, and three mentioned <italic>blinding</italic> [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>]. Only two studies noted <italic>inadequate outcome data</italic> [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref044" ref-type="bibr">44</xref>], and <italic>free of elective outcome reporting</italic> was mentioned in all studies. None of the studies commented on whether they were <italic>free of other biases</italic>. Consequently, the quality of each study was moderate, as was the quality of the body of evidence in general.</p></sec><sec id="sec019"><title>Suppressive effect of <italic>H</italic>. <italic>pylori</italic> eradication therapy on primary gastric cancer</title><p>Overall, eradication therapy of <italic>H</italic>. <italic>pylori</italic> infection significantly reduced the risk on primary gastric cancer (pooled risk ratio [RR], 0.67; 95% Confidence Interval [CI], 0.48 to 0.95 with low heterogeneity (I<sup>2</sup> = 0%) in <xref ref-type="table" rid="pone.0183321.t004">Table 4</xref> and <xref ref-type="fig" rid="pone.0183321.g002">Fig 2</xref>. A subgroup analysis, the pooled RR was significantly shown for RCTs of high quality, those within Asia, those in which the control group was given a placebo or no treatment, those that targeted subjects with a mean age between 41 and 50 years, and even those in which the mean study period exceeded 10 years.</p><table-wrap id="pone.0183321.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.t004</object-id><label>Table 4</label><caption><title>Effectiveness of Helicobacter pylori eradication therapy for gastric cancer prevention.</title></caption><alternatives><graphic id="pone.0183321.t004g" xlink:href="pone.0183321.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="3" colspan="1">Outcomes</th><th align="center" rowspan="3" colspan="1">Reference</th><th align="center" rowspan="3" colspan="1">No. of studies</th><th align="center" colspan="3" rowspan="1">Pooled risk ratio</th><th align="center" rowspan="1" colspan="1">Heterogeneity</th><th align="center" colspan="3" rowspan="1">Pooled risk difference</th><th align="center" rowspan="1" colspan="1">Heterogeneity</th><th align="center" rowspan="3" colspan="1">Statistical method by effect model</th><th align="center" colspan="3" rowspan="1">NNT</th><th align="center" rowspan="3" colspan="1">Quality of a body of evidence</th></tr><tr><th align="center" rowspan="2" colspan="1">Value</th><th align="center" colspan="2" rowspan="1">95%CI</th><th align="center" rowspan="2" colspan="1">I<sup>2</sup> value (%)</th><th align="center" rowspan="2" colspan="1">Value</th><th align="center" colspan="2" rowspan="1">95%CI</th><th align="center" rowspan="2" colspan="1">I<sup>2</sup> value (%)</th><th align="center" rowspan="2" colspan="1">Value</th><th align="center" colspan="2" rowspan="1">95%CI</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Overall</td><td align="center" rowspan="1" colspan="1">43&#x02013;49</td><td align="center" rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">0.67</td><td align="char" char="." rowspan="1" colspan="1">0.48</td><td align="char" char="." rowspan="1" colspan="1">0.95</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">125.5</td><td align="char" char="." rowspan="1" colspan="1">70.0</td><td align="char" char="." rowspan="1" colspan="1">800.9</td><td align="center" rowspan="24" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">High quality RCTs</td><td align="center" rowspan="1" colspan="1">43, 44, 47&#x02013;49</td><td align="center" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0.65</td><td align="char" char="." rowspan="1" colspan="1">0.45</td><td align="char" char="." rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">101.7</td><td align="char" char="." rowspan="1" colspan="1">57.4</td><td align="char" char="." rowspan="1" colspan="1">604.0</td></tr><tr><td align="right" rowspan="1" colspan="1">RCT in Japan</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.55</td><td align="char" char="." rowspan="1" colspan="1">0.09</td><td align="char" char="." rowspan="1" colspan="1">3.27</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="char" char="." rowspan="1" colspan="1">232.1</td><td align="char" char="." rowspan="1" colspan="1">79.8</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Studies within Asia</td><td align="center" rowspan="1" colspan="1">44, 46&#x02013;49</td><td align="center" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0.64</td><td align="char" char="." rowspan="1" colspan="1">0.45</td><td align="char" char="." rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">102.7</td><td align="char" char="." rowspan="1" colspan="1">59.6</td><td align="char" char="." rowspan="1" colspan="1">463.2</td></tr><tr><td align="right" rowspan="1" colspan="1">Studies outside of Asia</td><td align="center" rowspan="1" colspan="1">43, 45</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1.27</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">4.70</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">472.2</td><td align="char" char="." rowspan="1" colspan="1">85.7</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Annual healthy screening or good health</td><td align="center" rowspan="1" colspan="1">44&#x02013;46, 49</td><td align="center" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0.63</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">1.17</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">185.8</td><td align="char" char="." rowspan="1" colspan="1">88.4</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Giving placebo or no treatment to comparison group</td><td align="center" rowspan="1" colspan="1">44, 46&#x02013;49</td><td align="center" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0.64</td><td align="char" char="." rowspan="1" colspan="1">0.45</td><td align="char" char="." rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">102.7</td><td align="char" char="." rowspan="1" colspan="1">59.6</td><td align="char" char="." rowspan="1" colspan="1">463.2</td></tr><tr><td align="right" rowspan="1" colspan="1">Cases of gastric mucosal improvement after eradication</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.27</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">4.70</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="char" char="." rowspan="1" colspan="1">368.3</td><td align="char" char="." rowspan="1" colspan="1">70.1</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Patients with preneoplastic lesions</td><td align="center" rowspan="1" colspan="1">44, 47, 48</td><td align="center" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.69</td><td align="char" char="." rowspan="1" colspan="1">0.47</td><td align="char" char="." rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">77.7</td><td align="char" char="." rowspan="1" colspan="1">38.0</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Patients without preneoplastic lesions</td><td align="center" rowspan="1" colspan="1">43, 45, 46, 49</td><td align="center" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0.62</td><td align="char" char="." rowspan="1" colspan="1">0.27</td><td align="char" char="." rowspan="1" colspan="1">1.43</td><td align="center" rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">155.4</td><td align="char" char="." rowspan="1" colspan="1">90.1</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Participants' mean age, 41 to 50</td><td align="center" rowspan="1" colspan="1">44, 47</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0.65</td><td align="char" char="." rowspan="1" colspan="1">0.44</td><td align="char" char="." rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">87.7</td><td align="char" char="." rowspan="1" colspan="1">48.1</td><td align="char" char="." rowspan="1" colspan="1">794.6</td></tr><tr><td align="right" rowspan="1" colspan="1">Age 51 to 60</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">3.04</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="char" char="." rowspan="1" colspan="1">126.8</td><td align="char" char="." rowspan="1" colspan="1">70.1</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Gastric cancer, gastric type</td><td align="center" rowspan="1" colspan="1">43, 48</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.04</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">535.0</td><td align="center" colspan="2" rowspan="1">Uncalculatable</td></tr><tr><td align="right" rowspan="1" colspan="1">Gastric cancer, intestinal type</td><td align="center" rowspan="1" colspan="1">43, 48</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">3.04</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="char" char="." rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">535.0</td><td align="center" colspan="2" rowspan="1">Uncalculatable</td></tr><tr><td align="right" rowspan="1" colspan="1">Gastric cancer, cardiac type</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td></tr><tr><td align="right" rowspan="1" colspan="1">Gastric cancer, non cardiac type</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td></tr><tr><td align="right" rowspan="1" colspan="1">Annual follow-up of endoscopic examination</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" colspan="3" rowspan="1">Uncalculatable</td></tr><tr><td align="right" rowspan="1" colspan="1">Scheduled follow-up except annual endoscopic examination</td><td align="center" rowspan="1" colspan="1">44, 45, 48, 49</td><td align="center" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="char" char="." rowspan="1" colspan="1">0.40</td><td align="char" char="." rowspan="1" colspan="1">1.38</td><td align="center" rowspan="1" colspan="1">19</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">294.2</td><td align="char" char="." rowspan="1" colspan="1">102.2</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Research duration (mean), shorter than 5 years</td><td align="center" rowspan="1" colspan="1">43, 46</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0.55</td><td align="char" char="." rowspan="1" colspan="1">0.09</td><td align="char" char="." rowspan="1" colspan="1">3.27</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">M-H</td><td align="char" char="." rowspan="1" colspan="1">301.8</td><td align="char" char="." rowspan="1" colspan="1">100.7</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">5 to 10 years</td><td align="center" rowspan="1" colspan="1">44, 48</td><td align="center" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0.98</td><td align="char" char="." rowspan="1" colspan="1">0.25</td><td align="char" char="." rowspan="1" colspan="1">3.89</td><td align="center" rowspan="1" colspan="1">37</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">533.0</td><td align="char" char="." rowspan="1" colspan="1">105.7</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">Longer than 10 years</td><td align="center" rowspan="1" colspan="1">45, 47, 49</td><td align="center" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.65</td><td align="char" char="." rowspan="1" colspan="1">0.44</td><td align="char" char="." rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">82.5</td><td align="char" char="." rowspan="1" colspan="1">45.0</td><td align="char" char="." rowspan="1" colspan="1">833.3</td></tr><tr><td align="right" rowspan="1" colspan="1">Eradication therapy, PCA</td><td align="center" rowspan="1" colspan="1">43, 46&#x02013;49</td><td align="center" rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0.65</td><td align="char" char="." rowspan="1" colspan="1">0.44</td><td align="char" char="." rowspan="1" colspan="1">0.95</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">D-L</td><td align="char" char="." rowspan="1" colspan="1">86.9</td><td align="char" char="." rowspan="1" colspan="1">49.4</td><td align="char" char="." rowspan="1" colspan="1">489.3</td></tr><tr><td align="right" rowspan="1" colspan="1">PMA</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0.63</td><td align="char" char="." rowspan="1" colspan="1">0.25</td><td align="char" char="." rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">-0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.02</td><td align="char" char="." rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="char" char="." rowspan="1" colspan="1">201.5</td><td align="char" char="." rowspan="1" colspan="1">76.1</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr><tr><td align="right" rowspan="1" colspan="1">BMA</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.27</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">4.70</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">-0.01</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">Uncalculatable</td><td align="center" rowspan="1" colspan="1">-</td><td align="char" char="." rowspan="1" colspan="1">368.3</td><td align="char" char="." rowspan="1" colspan="1">70.1</td><td align="center" rowspan="1" colspan="1">&#x0221e;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>CI, confidence intervals; NNT, Number needed to treat; RCT, Randomized controlled trial; M-H, Mantel-Haenszel; D-L, DerSimonian-Laird</p></fn><fn id="t004fn002"><p>PCA, Proton pump inhibitor, clarithromycin, and amoxicillin; PMA, Proton pump inhibitor, metronidazole, and amoxicillin; BMA, bismuth, metronidazole, and amoxicillin</p></fn></table-wrap-foot></table-wrap><fig id="pone.0183321.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.g002</object-id><label>Fig 2</label><caption><title>Pooled risk difference (RD) in gastric cancer occurrence in patients with <italic>Helicobacter pylori</italic> infection.</title><p>I<sup>2</sup> value indicates heterogeneity of 33%. n = case of gastric cancer. N = group size.</p></caption><graphic xlink:href="pone.0183321.g002"/></fig><p>Overall, eradication therapy of <italic>H</italic>. <italic>pylori</italic> infection did not significantly reduce the risk on primary gastric cancer (pooled difference [RD], -0.00; 95% Confidence Interval [CI], -0.01 to 0.00 with low heterogeneity (I<sup>2</sup> = 33%) and NNT = 125.5 [95% CI: 70.0 to 800.9]). When the analysis was restricted to the five high-quality RCTs, pooled RD was -0.01 [95% CI: -0.02 to 0.00] (I<sup>2</sup> = 50%, NNT = 101.7 [95% CI: 57.4 to 604.0]). When analyzing the relationship between RR and follow-up period for the three studies with a mean follow-up period of at least 10 years [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], linear regression yielded a line with a positive slope (y (RR) = 0.4932x (year)&#x02013; 4.6888) (<xref ref-type="fig" rid="pone.0183321.g003">Fig 3</xref>). Besides, when analyzing the relationship between RD and follow-up period for the three studies with a mean follow-up period of at least 10 years [<xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0183321.ref049" ref-type="bibr">49</xref>], linear regression yielded a line with a positive slope (y (RD) = 1.0416x (year)&#x02013; 12.504) (<xref ref-type="fig" rid="pone.0183321.g004">Fig 4</xref>). This suggests that although the risk of cancer onset is higher in the control group than in the intervention group up to a follow-up period of 11.5 to 12 years, the relationship might be reversed beyond this point.</p><fig id="pone.0183321.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.g003</object-id><label>Fig 3</label><caption><title>Simple linear regression.</title><p>Risk ratio (y-axis) was plotted as a function of the mean follow-up period in the interventional and control groups of each study (x-axis), and a simple linear regression line was fitted using the least squares method. The point at which the risk of cancer occurrence in the interventional group exceeds that in the control group was calculated to be approximately 11.5 years. rr, risk ratio.</p></caption><graphic xlink:href="pone.0183321.g003"/></fig><fig id="pone.0183321.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.g004</object-id><label>Fig 4</label><caption><title>Simple linear regression.</title><p>Risk difference (y-axis) was plotted as a function of the mean follow-up period in the interventional and control groups of each study (x-axis), and a simple linear regression line was fitted using the least squares method. The point at which the risk of cancer occurrence in the interventional group exceeds that in the control group was calculated to be approximately 12 years. rd, risk difference.</p></caption><graphic xlink:href="pone.0183321.g004"/></fig></sec><sec id="sec020"><title>Publication bias</title><p>Funnel-plot analysis, Begg&#x02019;s test, and Egger&#x02019;s test were performed to evaluate the potential for publication bias in terms of overall RD (<xref ref-type="fig" rid="pone.0183321.g005">Fig 5</xref>). The funnel-plot did not show an asymmetric pattern. Neither of the statistical tests revealed significant publication bias (p = 0.348, p = 0.610, respectively).</p><fig id="pone.0183321.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183321.g005</object-id><label>Fig 5</label><caption><title>Publication bias of trials reporting gastric cancer in patients with <italic>Helicobacter pylori</italic> infection.</title><p>OR, Odds Ratio.</p></caption><graphic xlink:href="pone.0183321.g005"/></fig></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>In this study, we conducted a systematic review of whether <italic>H</italic>. <italic>pylori</italic> eradication therapy suppresses the occurrence of primary gastric cancer in patients whose gastric cancer was not diagnosed endoscopically. Three RCTs [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>, <xref rid="pone.0183321.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0183321.ref048" ref-type="bibr">48</xref>] were added to the meta-analysis by Fuccio <italic>et al</italic>.[<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>] in 2009, and one [<xref rid="pone.0183321.ref043" ref-type="bibr">43</xref>] to the meta-analyses by Ford <italic>et al</italic>.[<xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0183321.ref010" ref-type="bibr">10</xref>] in 2014 and 2015. A meta-analysis of the seven articles ultimately included revealed that, whereas the gastric cancer suppressing effect of eradication therapy was comparable to that of previous research in terms of RR, the effect size in terms of RD, which was not assessed in previous studies, was minor and not statistically significant. Overall NNT was 125, and subgroup analyses were approximately from 100 to 300. Showing these values, we think the effectiveness of eradication of <italic>Helicobacter pylori</italic> to prevent primary gastric cancer was relatively low. This trend was observed in all subgroup analyses in <xref ref-type="table" rid="pone.0183321.t004">Table 4</xref>.</p><p>In this study, the overall pooled RR for the suppression of gastric cancer by <italic>H</italic>. <italic>pylori</italic> eradication was 0.67 (95% CI: 0.48 to 0.95), which was comparable to that of previous studies. However, when expressed in terms of RD, the overall pooled RD was -0.00 (95% CI: -0.01 to 0.00), i.e., the effect was slight and not statistically significant. It is common that "Relative Risk obtained from the same data looks larger than Risk Difference". Apart from whether it is one case symbolically seen in the present research question and whether it is deliberate or not intentional, in the previous study both RCT and meta-analysis were only indicators of risk ratio. The magnitude of the effect such as risk ratio 0.6&#x02013;0.7 was emphasized, and the tone of the discussion was to justify the aggressive intervention. Although we used the same data to analyze pooled risk ratio and risk difference, pooled risk ratio was statistically significant but pooled risk difference was not. When the event-incidence was rare with meta-analysis, in another study, pooled risk ratio was statistically significant but pooled risk difference was not like our study [<xref rid="pone.0183321.ref053" ref-type="bibr">53</xref>]. We thought that the association between pooled risk ratio and risk difference showed discrepancy because we used data of rare events. In fact, Lane, <italic>et al</italic> showed that this discrepancy occurred when the methods of statistical tests in the meta-analysis were the differences and outcome incidence of the original data used in randomized controlled trials was rare. Main purpose of our study is to facilitate careful discussion on the expected magnitude of the effect of sterilization by <italic>H</italic>. <italic>pylori</italic> eradication to prevent primary gastric cancer comparing two risk indices that have been rarely mentioned before. We think that this phenomenon can be called a new outcome- reporting bias in risk communication. Many epidemiological findings, including those from clinical trials, are expressed in terms of RR; however, it has been repeatedly pointed out that compared with absolute risk, this index overestimates the association. [<xref rid="pone.0183321.ref021" ref-type="bibr">21</xref>]. For example, in a clinical trial by Lipid Research Clinics reported in 1982 [<xref rid="pone.0183321.ref054" ref-type="bibr">54</xref>], a 19% reduction in the risk of ischemic heart disease due to a cholesterol-reducing drug was emphasized. However, this was expressed in terms of relative risk reduction (RRR); the absolute risk reduction (ARR) was 1.6%. A similar report also emphasized an RRR of 31% over an ARR of 2.3% [<xref rid="pone.0183321.ref055" ref-type="bibr">55</xref>]. The RRR used in these studies, although not identical to relative risk, is a ratio-based index; this expression was likely used with the intent to strengthen reader impressions. Given these findings, the FDA proposed the following in a 2011 report when communicating risk: &#x0201c;Provide absolute risks, not just relative risks. Patients are unduly influenced when risk information is presented using a relative risk approach; this can result in suboptimal decisions&#x0201d; [<xref rid="pone.0183321.ref013" ref-type="bibr">13</xref>]. The RR results presented herein do not deny the effectiveness of <italic>H</italic>. <italic>pylori</italic> eradication in preventing cancer. Nonetheless, the results for absolute risk (AR) suggest that we should be cautious regarding the effect size and its level of certainty as evidence. Typically, the problem with selective reporting has been outcome reporting bias, in which numerous outcomes are measured and only those variables attaining statistical significance are published [<xref rid="pone.0183321.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pone.0183321.ref058" ref-type="bibr">58</xref>]. Previous studies of <italic>H</italic>. <italic>pylori</italic> eradication presented their results only as a ratio index that emphasizes its effect could be pointed out as a new selective reporting issue distinct from prevailing problems.</p><p>NNT is a treatment effect index based on ARR. Fuccio <italic>et al</italic>.[<xref rid="pone.0183321.ref006" ref-type="bibr">6</xref>] or Lee <italic>et al</italic>. [<xref rid="pone.0183321.ref011" ref-type="bibr">11</xref>] did not show NNT in their report. Although Ford <italic>et al</italic>.[<xref rid="pone.0183321.ref009" ref-type="bibr">9</xref>] showed NNT separately by country, their interpretation of this in their report was that the treatment would reduce the occurrence of gastric cancer within Asia. Obtaining the NNT for each population is appropriate because this index is influenced by the AR of a disease in a target population. However, a stable NNT cannot be obtained from findings in a single-population study that lacks power. To make evidence-based decisions, it will be necessary to alleviate the large impact that RR has on readers by obtaining NNT from an integrated RD and interpreting the results within the article.</p><p>To whom can we recommend <italic>H</italic>. <italic>pylori</italic> eradication therapy for suppressing the occurrence of gastric cancer? Eradication therapy is necessary for patients who have just undergone early-stage gastric cancer surgery [<xref rid="pone.0183321.ref059" ref-type="bibr">59</xref>&#x02013;<xref rid="pone.0183321.ref062" ref-type="bibr">62</xref>] and is well-established for patients who have undergone endoscopic therapy for this type of cancer [<xref rid="pone.0183321.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0183321.ref063" ref-type="bibr">63</xref>]. This study, which targeted asymptomatic patients infected with <italic>H</italic>. <italic>pylori</italic>, predicted the following: first, that the reduction in the risk of gastric cancer by <italic>H</italic>. <italic>pylori</italic> eradication therapy would be at least 30% in terms of RR, similar to that of previous findings, but would be slight and statistically insignificant in terms of RD; and second, that after eradication, a suppressive effect on gastric cancer would likely occur in the short term but diminish in the long term due to increased occurrence of cancer from aging (<xref ref-type="fig" rid="pone.0183321.g003">Fig 3</xref>). Therefore, those with severe gastric mucosal atrophy or precancerous lesions, which are relatively elderly high-risk groups, tend not to benefit from the treatment effects. In contrast, young individuals without atrophy might be expected to benefit from the effects of eradication therapy in preventing gastric cancer. In the long-term, endoscopy will likely be necessary because cancer begins to occur more frequently with age, even in the intervention group.</p><p>This study has several limitations. First, the mean study periods of the RCTs used were short (6&#x02013;7 years). In a review which cited an article by Graham <italic>et al</italic>. and the fact that the occurrence of cancer had also been demonstrated in RCTs with long-term follow-up, Tan <italic>et al</italic>. [<xref rid="pone.0183321.ref064" ref-type="bibr">64</xref>] stated that cohort studies on the same topic should also be referred to in evaluating the gastric cancer suppressing effects of <italic>H</italic>. <italic>pylori</italic> eradication therapy. Considering that many of the RCTs used here were completed within a few years, a re-examination including a cohort study with a longer observation period would be meaningful. For observational studies, pre-registration has not become as widespread as it has for RCTs; such studies should also be interpreted cautiously because publication bias is more severe than it is for interventional studies, and because cohort studies, given their high bias risk, may show results that diverge from true results. Second, the eradication effect could vary depending on histopathology, i.e., gastritis, atrophy, intestinal metaplasia, or dysplasia. However, these could not be clearly distinguished in the present study.</p><p>There is ABC classification for assessing gastric cancer risk and evaluating the degree of gastric mucosal atrophy objectively and quantitatively [<xref rid="pone.0183321.ref065" ref-type="bibr">65</xref>]. In our study, we couldn&#x02019;t compare the degree of gastric mucosal atrophy quantitatively. Among youths, a <italic>H</italic>. <italic>pylori</italic> carrier without gastric mucosal atrophy could possibly lower the risk of primary gastric cancer [<xref rid="pone.0183321.ref066" ref-type="bibr">66</xref>]. This problem could be addressed by future studies with the development of a standardized method for tissue evaluation.</p><p>From the present study, we conclude that the suppressive effect of <italic>H</italic>. <italic>pylori</italic> eradication therapy on the occurrence of primary gastric cancer was statistically significant and comparable to that of previous studies in terms of estimated RR. However, in terms of RD, the effect size was minor and not statistically significant. At this point, caution must be exercised when promoting evidence-based eradication measures.</p></sec><sec sec-type="supplementary-material" id="sec022"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0183321.s001"><label>S1 Table</label><caption><title>PRISMA-2009-Checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0183321.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AR</term><def><p>Absolute risk</p></def></def-item><def-item><term>ARR</term><def><p>Absolute risk reduction</p></def></def-item><def-item><term>BMA</term><def><p>bismuth, metronidazole, and amoxicillin</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>COI</term><def><p>Conflict of interest</p></def></def-item><def-item><term>DDW</term><def><p>Digestive Disease Week</p></def></def-item><def-item><term>EMBASE</term><def><p>Excerpta Medica database</p></def></def-item><def-item><term>EMR</term><def><p>Endoscopic mucosal resection</p></def></def-item><def-item><term>ESD</term><def><p>Endoscopic submucosal dissection</p></def></def-item><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term>ITT</term><def><p>Intention to treat</p></def></def-item><def-item><term>NNT</term><def><p>Number needed to treat</p></def></def-item><def-item><term>PCA</term><def><p>Proton pump inhibitor, clarithromycin, and amoxicillin</p></def></def-item><def-item><term>PMA</term><def><p>Proton pump inhibitor, metronidazole, and amoxicillin</p></def></def-item><def-item><term>PPI</term><def><p>Proton pump inhibitor</p></def></def-item><def-item><term>PRISMA</term><def><p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>RD</term><def><p>Risk difference</p></def></def-item><def-item><term>RR</term><def><p>Risk ratio</p></def></def-item><def-item><term>RRR</term><def><p>Relative risk reduction</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0183321.ref001"><label>1</label><mixed-citation publication-type="book"><collab>International Agency for Research on Cancer</collab>. <collab>World Health Organization</collab>. <chapter-title>Infection with <italic>Helicobacter pylori</italic></chapter-title> In: <source>Schistosomes, liver flukes and <italic>Helicobacter pylori</italic></source>. <publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC</publisher-name>, <year>1994</year>, <fpage>177</fpage>&#x02013;<lpage>202</lpage>.</mixed-citation></ref><ref id="pone.0183321.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Correa</surname><given-names>P</given-names></name>. <article-title>Human gastric carcinogenesis: a multistep and multifactorial process&#x02014;First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention</article-title>. <source>Cancer Res</source>
<year>1992</year>; <volume>52</volume>: <fpage>6735</fpage>&#x02013;<lpage>40</lpage>. .<pub-id pub-id-type="pmid">1458460</pub-id></mixed-citation></ref><ref id="pone.0183321.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Take</surname><given-names>S</given-names></name>, <name><surname>Mizuno</surname><given-names>M</given-names></name>, <name><surname>Ishiki</surname><given-names>K</given-names></name>, <name><surname>Nagahara</surname><given-names>Y</given-names></name>, <name><surname>Yoshida</surname><given-names>T</given-names></name>, <name><surname>Yokota</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>The effect of eradicating <italic>helicobacter pylori</italic> on the development of gastric cancer in patients with peptic ulcer disease</article-title>. <source>Am J Gastroenterol</source>
<year>2005</year>; <volume>100</volume>:<fpage>1037</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1572-0241.2005.41384.x">10.1111/j.1572-0241.2005.41384.x</ext-link></comment> .<pub-id pub-id-type="pmid">15842576</pub-id></mixed-citation></ref><ref id="pone.0183321.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Take</surname><given-names>S</given-names></name>, <name><surname>Mizuno</surname><given-names>M</given-names></name>, <name><surname>Ishiki</surname><given-names>K</given-names></name>, <name><surname>Nagahara</surname><given-names>Y</given-names></name>, <name><surname>Yoshida</surname><given-names>T</given-names></name>, <name><surname>Yokota</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after <italic>Helicobacter pylori</italic> eradication therapy in patients with peptic ulcer diseases</article-title>. <source>J Gastroenterol</source>
<year>2007</year>; <volume>42</volume>
<issue>Suppl 17</issue>: <fpage>21</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00535-006-1924-9">10.1007/s00535-006-1924-9</ext-link></comment> .<pub-id pub-id-type="pmid">17238021</pub-id></mixed-citation></ref><ref id="pone.0183321.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Fukase</surname><given-names>K</given-names></name>, <name><surname>Kato</surname><given-names>M</given-names></name>, <name><surname>Kikuchi</surname><given-names>S</given-names></name>, <name><surname>Inoue</surname><given-names>K</given-names></name>, <name><surname>Uemura</surname><given-names>N</given-names></name>, <name><surname>Okamoto</surname><given-names>S</given-names></name>, <etal>et al</etal>
<collab>Japan Gast Study Group</collab>. <article-title>Effect of eradication of <italic>Helicobacter pylori</italic> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial</article-title>. <source>Lancet</source>
<year>2008</year>; <volume>372</volume>: <fpage>392</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(08)61159-9">10.1016/S0140-6736(08)61159-9</ext-link></comment> .<pub-id pub-id-type="pmid">18675689</pub-id></mixed-citation></ref><ref id="pone.0183321.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Fuccio</surname><given-names>L</given-names></name>, <name><surname>Zagari</surname><given-names>RM</given-names></name>, <name><surname>Eusebi</surname><given-names>LH</given-names></name>, <name><surname>Laterza</surname><given-names>L</given-names></name>, <name><surname>Cennamo</surname><given-names>V</given-names></name>, <name><surname>Ceroni</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Meta-analysis: can <italic>Helicobacter pylori</italic> eradication treatment reduce the risk for gastric cancer?</article-title>
<source>Ann Intern Med</source>
<year>2009</year>; <volume>151</volume>: <fpage>121</fpage>&#x02013;<lpage>8</lpage>. .<pub-id pub-id-type="pmid">19620164</pub-id></mixed-citation></ref><ref id="pone.0183321.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Leung</surname><given-names>WK</given-names></name>, <name><surname>Lin</surname><given-names>SR</given-names></name>, <name><surname>Ching</surname><given-names>JY</given-names></name>, <name><surname>To</surname><given-names>KF</given-names></name>, <name><surname>Ng</surname><given-names>EK</given-names></name>, <name><surname>Chan</surname><given-names>FK</given-names></name>, <etal>et al</etal>
<article-title>Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication</article-title>. <source>Gut</source>
<year>2004</year>; <volume>53</volume>: <fpage>1244</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gut.2003.034629">10.1136/gut.2003.034629</ext-link></comment> .<pub-id pub-id-type="pmid">15306578</pub-id></mixed-citation></ref><ref id="pone.0183321.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Ford</surname><given-names>AC</given-names></name>, <name><surname>Moayyedi</surname><given-names>P</given-names></name>. <article-title>Redundant data in the meta-analysis on <italic>Helicobacter pylori</italic> eradication</article-title>. <source>Ann Intern Med</source>
<year>2009</year>; <volume>151</volume>: <fpage>513</fpage> .<pub-id pub-id-type="pmid">19805775</pub-id></mixed-citation></ref><ref id="pone.0183321.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Ford</surname><given-names>AC</given-names></name>, <name><surname>Forman</surname><given-names>D</given-names></name>, <name><surname>Hunt</surname><given-names>RH</given-names></name>, <name><surname>Yuan</surname><given-names>Y</given-names></name>, <name><surname>Moayyedi</surname><given-names>P</given-names></name>. <article-title><italic>Helicobacter pylori</italic> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials</article-title>. <source>BMJ</source>
<year>2014</year>; <volume>348</volume>: <fpage>g3174</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.g3174">10.1136/bmj.g3174</ext-link></comment> .<pub-id pub-id-type="pmid">24846275</pub-id></mixed-citation></ref><ref id="pone.0183321.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ford</surname><given-names>AC</given-names></name>, <name><surname>Forman</surname><given-names>D</given-names></name>, <name><surname>Hunt</surname><given-names>R</given-names></name>, <name><surname>Yuan</surname><given-names>Y</given-names></name>, <name><surname>Moayyedi</surname><given-names>P</given-names></name>. <article-title><italic>Helicobacter pylori</italic> eradication for the prevention of gastric neoplasia</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2015</year>; <volume>7</volume>: <fpage>CD005583</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD005583.pub2">10.1002/14651858.CD005583.pub2</ext-link></comment>
<pub-id pub-id-type="pmid">26198377</pub-id></mixed-citation></ref><ref id="pone.0183321.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>YC</given-names></name>, <name><surname>Chiang</surname><given-names>TH</given-names></name>, <name><surname>Chou</surname><given-names>CK</given-names></name>, <name><surname>Tu</surname><given-names>YK</given-names></name>, <name><surname>Liao</surname><given-names>WC</given-names></name>, <name><surname>Wu</surname><given-names>MS</given-names></name>, <etal>et al</etal>
<article-title>Association Between <italic>Helicobacter pylori</italic> Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis</article-title>. <source>Gastroenterology</source>. <year>2016</year>; <volume>150</volume>: <fpage>1113</fpage>&#x02013;<lpage>1124.e5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2016.01.028">10.1053/j.gastro.2016.01.028</ext-link></comment> .<pub-id pub-id-type="pmid">26836587</pub-id></mixed-citation></ref><ref id="pone.0183321.ref012"><label>12</label><mixed-citation publication-type="book"><name><surname>Porta</surname><given-names>M</given-names></name>, ed. <source>A Dictionary of Epidemiology</source>, <edition>six edition</edition>: <publisher-name>Oxford University Press</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="pone.0183321.ref013"><label>13</label><mixed-citation publication-type="other">Fagerlin A (2011).&#x0201d;Chapter 7: Quantitative Information&#x0201d;. In: Fischhoff B, Brewer NT, Downs JS (eds.) Communicating Risks and Benefits: An Evidence-Based User's Guide, 57&#x02013;61. Annapolis: Food and Drug Administration (FDA). <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM268069.pdf">http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM268069.pdf</ext-link></mixed-citation></ref><ref id="pone.0183321.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Naylor</surname><given-names>CD</given-names></name>, <name><surname>Chen</surname><given-names>E</given-names></name>, <name><surname>Strauss</surname><given-names>B</given-names></name>. <article-title>Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?</article-title>
<source>Ann Intern Med</source>. <year>1992</year>; <volume>117</volume>: <fpage>916</fpage>&#x02013;<lpage>21</lpage>. .<pub-id pub-id-type="pmid">1443954</pub-id></mixed-citation></ref><ref id="pone.0183321.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Elting</surname><given-names>LS</given-names></name>, <name><surname>Martin</surname><given-names>CG</given-names></name>, <name><surname>Cantor</surname><given-names>SB</given-names></name>, <name><surname>Rubenstein</surname><given-names>EB</given-names></name>. <article-title>Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures</article-title>. <source>BMJ</source>. <year>1999</year>; <volume>318</volume>: <fpage>1527</fpage>&#x02013;<lpage>31</lpage>. .<pub-id pub-id-type="pmid">10356010</pub-id></mixed-citation></ref><ref id="pone.0183321.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Schulz</surname><given-names>KF</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name>; <collab>CONSORT Group</collab>. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title>. <source>Ann Intern Med</source>. <year>2010</year>; <volume>152</volume>: <fpage>726</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7326/0003-4819-152-11-201006010-00232">10.7326/0003-4819-152-11-201006010-00232</ext-link></comment> .<pub-id pub-id-type="pmid">20335313</pub-id></mixed-citation></ref><ref id="pone.0183321.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Nuovo</surname><given-names>J</given-names></name>, <name><surname>Melnikow</surname><given-names>J</given-names></name>, <name><surname>Chang</surname><given-names>D</given-names></name>. <article-title>Reporting number needed to treat and absolute risk reduction in randomized controlled trials</article-title>. <source>JAMA</source>. <year>2002</year>; <volume>287</volume>: <fpage>2813</fpage>&#x02013;<lpage>4</lpage>. .<pub-id pub-id-type="pmid">12038920</pub-id></mixed-citation></ref><ref id="pone.0183321.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Schechtman</surname><given-names>E</given-names></name>. <article-title>Odds ratio, relative risk, absolute risk reduction, and the number needed to treat&#x02014;which of these should we use?</article-title>
<source>Value Health</source>. <year>2002</year>; <volume>5</volume>: <fpage>431</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/J.1524-4733.2002.55150.x">10.1046/J.1524-4733.2002.55150.x</ext-link></comment> .<pub-id pub-id-type="pmid">12201860</pub-id></mixed-citation></ref><ref id="pone.0183321.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Citrome</surname><given-names>L</given-names></name>. <article-title>Relative vs. absolute measures of benefit and risk: what's the difference?</article-title>
<source>Acta Psychiatr Scand</source>. <year>2010</year>; <volume>121</volume>: <fpage>94</fpage>&#x02013;<lpage>102</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-0447.2009.01449.x">10.1111/j.1600-0447.2009.01449.x</ext-link></comment> .<pub-id pub-id-type="pmid">19694632</pub-id></mixed-citation></ref><ref id="pone.0183321.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Nakayama</surname><given-names>T</given-names></name>. <article-title>Under-reporting of attributable risk and reporting of the risk ratio in epidemiologic literature</article-title>. <source>Epidemiology</source>. <year>2000</year>; <volume>11</volume>: <fpage>366</fpage>&#x02013;<lpage>7</lpage>. .<pub-id pub-id-type="pmid">10784264</pub-id></mixed-citation></ref><ref id="pone.0183321.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Nakayama</surname><given-names>T</given-names></name>, <name><surname>Zaman</surname><given-names>MM</given-names></name>, <name><surname>Tanaka</surname><given-names>H</given-names></name>. <article-title>Reporting of attributable and relative risks, 1966&#x02013;97</article-title>. <source>Lancet</source>. <year>1998</year>; <volume>351</volume>: <fpage>1179</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(05)79123-6">10.1016/S0140-6736(05)79123-6</ext-link></comment> .<pub-id pub-id-type="pmid">9643696</pub-id></mixed-citation></ref><ref id="pone.0183321.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Gigerenzer</surname><given-names>G</given-names></name>, <name><surname>Wegwarth</surname><given-names>O</given-names></name>, <name><surname>Feufel</surname><given-names>M</given-names></name>. <article-title>Misleading communication of risk</article-title>. <source>BMJ</source>. <year>2010</year>; <volume>341</volume>: <fpage>c4830</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.c4830">10.1136/bmj.c4830</ext-link></comment> .<pub-id pub-id-type="pmid">20940219</pub-id></mixed-citation></ref><ref id="pone.0183321.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Liberati</surname><given-names>A</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>; <collab>PRISMA Group</collab>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>Ann Intern Med</source>
<year>2009</year>; <volume>151</volume>: <fpage>264</fpage>&#x02013;<lpage>9</lpage>. .<pub-id pub-id-type="pmid">19622511</pub-id></mixed-citation></ref><ref id="pone.0183321.ref024"><label>24</label><mixed-citation publication-type="other">JMAS (Japan Medical Abstracts Society, <ext-link ext-link-type="uri" xlink:href="http://login.jamas.or.jp/">http://login.jamas.or.jp/</ext-link>)</mixed-citation></ref><ref id="pone.0183321.ref025"><label>25</label><mixed-citation publication-type="other">Cochrane Central Register of Controlled Trials, <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/cochranelibrary/search?searchRow.searchOptions.searchProducts=clinicalTrialsDoi">http://onlinelibrary.wiley.com/cochranelibrary/search?searchRow.searchOptions.searchProducts=clinicalTrialsDoi</ext-link></mixed-citation></ref><ref id="pone.0183321.ref026"><label>26</label><mixed-citation publication-type="other">metaRegister of Controlled Trials, <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</ext-link></mixed-citation></ref><ref id="pone.0183321.ref027"><label>27</label><mixed-citation publication-type="other">ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov</ext-link>.</mixed-citation></ref><ref id="pone.0183321.ref028"><label>28</label><mixed-citation publication-type="other">controlled-trials.com, <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/">http://www.controlled-trials.com/</ext-link></mixed-citation></ref><ref id="pone.0183321.ref029"><label>29</label><mixed-citation publication-type="other">UMIN (University Hospital Medical Information Network in Japan, <ext-link ext-link-type="uri" xlink:href="http://www.umin.ac.jp/ctr/index-j.htm">http://www.umin.ac.jp/ctr/index-j.htm</ext-link>)</mixed-citation></ref><ref id="pone.0183321.ref030"><label>30</label><mixed-citation publication-type="other">JMACCT (Japan Medical Association Clinical Trial Registry, <ext-link ext-link-type="uri" xlink:href="https://dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRS01/JMACTRS01.aspx?kbn=4">https://dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRS01/JMACTRS01.aspx?kbn=4</ext-link>)</mixed-citation></ref><ref id="pone.0183321.ref031"><label>31</label><mixed-citation publication-type="other">JAPIC (Japan Pharmaceutical Information Center, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.jp/user/cte_main.jsp">http://clinicaltrials.jp/user/cte_main.jsp</ext-link>)</mixed-citation></ref><ref id="pone.0183321.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>T</given-names></name>, <name><surname>Hopewell</surname><given-names>S</given-names></name>. <article-title>Methods for obtaining unpublished data</article-title>. <source><italic>Cochrane Database Syst Rev</italic></source>
<year>2011</year>; <volume>11</volume>: <fpage>MR000027</fpage>.</mixed-citation></ref><ref id="pone.0183321.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Dixon</surname><given-names>MF</given-names></name>, <name><surname>Genta</surname><given-names>RM</given-names></name>, <name><surname>Yardley</surname><given-names>JH</given-names></name>, <name><surname>Correa</surname><given-names>P</given-names></name>. <article-title>Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994</article-title>. <source>Am J Surg Pathol</source>
<year>1996</year>; <volume>20</volume>: <fpage>1161</fpage>&#x02013;<lpage>81</lpage>. .<pub-id pub-id-type="pmid">8827022</pub-id></mixed-citation></ref><ref id="pone.0183321.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Jadad</surname><given-names>AR</given-names></name>, <name><surname>Moore</surname><given-names>RA</given-names></name>, <name><surname>Carroll</surname><given-names>D</given-names></name>, <name><surname>Jenkinson</surname><given-names>C</given-names></name>, <name><surname>Reynolds</surname><given-names>DJ</given-names></name>, <name><surname>Gavaghan</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title>
<source>Control Clin Trials</source>
<year>1996</year>; <volume>17</volume>: <fpage>1</fpage>&#x02013;<lpage>12</lpage>. .<pub-id pub-id-type="pmid">8721797</pub-id></mixed-citation></ref><ref id="pone.0183321.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Guyatt</surname><given-names>GH</given-names></name>, <name><surname>Oxman</surname><given-names>AD</given-names></name>, <name><surname>Vist</surname><given-names>G</given-names></name>, <name><surname>Kunz</surname><given-names>R</given-names></name>, <name><surname>Brozek</surname><given-names>J</given-names></name>, <name><surname>Alonso-Coello</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>GRADE guidelines: 4. Tating the quality of evidence-study limitations (risk of bias)</article-title>. <source>J Clin Epidemiol</source>
<year>2011</year>; <volume>64</volume>: <fpage>407</fpage>&#x02013;<lpage>415</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jclinepi.2010.07.017">10.1016/j.jclinepi.2010.07.017</ext-link></comment> .<pub-id pub-id-type="pmid">21247734</pub-id></mixed-citation></ref><ref id="pone.0183321.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Greenland</surname><given-names>S</given-names></name>, <name><surname>Robins</surname><given-names>JM</given-names></name>. <article-title>Estimation of a common effect parameter from sparse follow-up data</article-title>. <source>Biometrics</source>
<year>1985</year>; <volume>41</volume>: <fpage>55</fpage>&#x02013;<lpage>68</lpage>. .<pub-id pub-id-type="pmid">4005387</pub-id></mixed-citation></ref><ref id="pone.0183321.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JP</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Measuring incomsistency in meta-analysis</article-title>. <source>BMJ</source>
<year>2003</year>; <volume>327</volume>: <fpage>557</fpage>&#x02013;<lpage>560</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.327.7414.557">10.1136/bmj.327.7414.557</ext-link></comment> .<pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></ref><ref id="pone.0183321.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>DerSimonian</surname><given-names>R</given-names></name>, <name><surname>Laird</surname><given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>
<year>1986</year>; <volume>7</volume>: <fpage>177</fpage>&#x02013;<lpage>188</lpage>. .<pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation></ref><ref id="pone.0183321.ref039"><label>39</label><mixed-citation publication-type="book"><name><surname>Light</surname><given-names>RJ</given-names></name>, <name><surname>Pilemer</surname><given-names>DB</given-names></name>. <source>Summing Up: The Science of Reviewing Research</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>; <year>1984</year>.</mixed-citation></ref><ref id="pone.0183321.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Begg</surname><given-names>CB</given-names></name>, <name><surname>Mazumdar</surname><given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>
<year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>&#x02013;<lpage>1101</lpage>. .<pub-id pub-id-type="pmid">7786990</pub-id></mixed-citation></ref><ref id="pone.0183321.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Davey Smith</surname><given-names>G</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Minder</surname><given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>
<year>1997</year>; <volume>315</volume>: <fpage>629</fpage>&#x02013;<lpage>634</lpage>. .<pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="pone.0183321.ref042"><label>42</label><mixed-citation publication-type="book"><collab>StataCorp</collab>. <year>2015</year>
<source>Stata Statistical Software: Release 14</source>. <publisher-loc>College Station, TX</publisher-loc>: <publisher-name>StataCorp LP</publisher-name>.</mixed-citation></ref><ref id="pone.0183321.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Miehlke</surname><given-names>S</given-names></name>, <name><surname>Kirsch</surname><given-names>C</given-names></name>, <name><surname>Dragosics</surname><given-names>B</given-names></name>, <name><surname>Gschwantler</surname><given-names>M</given-names></name>, <name><surname>Oberhuber</surname><given-names>G</given-names></name>, <name><surname>Antos</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title><italic>Helicobacter pylori</italic> and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study)</article-title>. <source>World J Gastroenterol</source>
<year>2001</year>; <volume>7</volume>: <fpage>243</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v7.i2.243">10.3748/wjg.v7.i2.243</ext-link></comment> .<pub-id pub-id-type="pmid">11819768</pub-id></mixed-citation></ref><ref id="pone.0183321.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>BC</given-names></name>, <name><surname>Lam</surname><given-names>SK</given-names></name>, <name><surname>Wong</surname><given-names>WM</given-names></name>, <name><surname>Chen</surname><given-names>JS</given-names></name>, <name><surname>Zheng</surname><given-names>TT</given-names></name>, <name><surname>Feng</surname><given-names>RE</given-names></name>, <etal>et al</etal>
<collab>China Gastric Cancer Study Group</collab>. <article-title><italic>Helicobacter pylori</italic> eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2004</year>; <volume>291</volume>: <fpage>187</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jama.291.2.187">10.1001/jama.291.2.187</ext-link></comment> .<pub-id pub-id-type="pmid">14722144</pub-id></mixed-citation></ref><ref id="pone.0183321.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Mera</surname><given-names>R</given-names></name>, <name><surname>Fontham</surname><given-names>ET</given-names></name>, <name><surname>Bravo</surname><given-names>LE</given-names></name>, <name><surname>Bravo</surname><given-names>JC</given-names></name>, <name><surname>Piazuelo</surname><given-names>MB</given-names></name>, <name><surname>Camargo</surname><given-names>MC</given-names></name>, <etal>et al</etal>
<article-title>Long term follow up of patients treated for <italic>Helicobacter pylori</italic> infection</article-title>. <source>Gut</source>
<year>2005</year>; <volume>54</volume>: <fpage>1536</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gut.2005.072009">10.1136/gut.2005.072009</ext-link></comment> .<pub-id pub-id-type="pmid">15985559</pub-id></mixed-citation></ref><ref id="pone.0183321.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>D</given-names></name>, <name><surname>Boku</surname><given-names>N</given-names></name>, <name><surname>Fujioka</surname><given-names>T</given-names></name>. <article-title>Impact of <italic>H</italic>. <italic>Pylori</italic> Eradication on Gastric Prevention: Endoscopic Results of the Japanese Intervention Trial (JITHP-Study). a Randomized Multi-Center Trial</article-title>. <source>Gastroenterol</source>
<year>2005</year>; <volume>128</volume>(<issue>4 Suppl 2</issue>): <fpage>A4</fpage>.</mixed-citation></ref><ref id="pone.0183321.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>JL</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Brown</surname><given-names>LM</given-names></name>, <name><surname>Li</surname><given-names>JY</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>, <name><surname>Pan</surname><given-names>KF</given-names></name>, <etal>et al</etal>
<article-title>Fifteen-year effects of <italic>Helicobacter pylori</italic>, garlic, and vitamin treatments on gastric cancer incidence and mortality</article-title>. <source>J Natl Cancer Inst</source>
<year>2012</year>; <volume>104</volume>: <fpage>488</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jnci/djs003">10.1093/jnci/djs003</ext-link></comment> .<pub-id pub-id-type="pmid">22271764</pub-id></mixed-citation></ref><ref id="pone.0183321.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>BC</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Ma</surname><given-names>JL</given-names></name>, <name><surname>Pan</surname><given-names>KF</given-names></name>, <name><surname>Li</surname><given-names>JY</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Effects of selective COX-2 inhibitor and <italic>Helicobacter pylori</italic> eradication on precancerous gastric lesions</article-title>. <source>Gut</source>
<year>2012</year>; <volume>61</volume>: <fpage>812</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gutjnl-2011-300154">10.1136/gutjnl-2011-300154</ext-link></comment> .<pub-id pub-id-type="pmid">21917649</pub-id></mixed-citation></ref><ref id="pone.0183321.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>L</given-names></name>, <name><surname>Lin</surname><given-names>S</given-names></name>, <name><surname>Ding</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>X</given-names></name>, <name><surname>Jin</surname><given-names>Z</given-names></name>, <name><surname>Cui</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Relationship of <italic>Helicobacter pylori</italic> eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study</article-title>. <source>Chin Med J</source>
<year>2014</year>; <volume>127</volume>: <fpage>1454</fpage>&#x02013;<lpage>8</lpage>. .<pub-id pub-id-type="pmid">24762588</pub-id></mixed-citation></ref><ref id="pone.0183321.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Correa</surname><given-names>P</given-names></name>, <name><surname>Fontham</surname><given-names>ET</given-names></name>, <name><surname>Bravo</surname><given-names>JC</given-names></name>, <name><surname>Bravo</surname><given-names>LE</given-names></name>, <name><surname>Ruiz</surname><given-names>B</given-names></name>, <name><surname>Zarama</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-<italic>helicobacter pylori</italic> therapy</article-title>. <source>J Natl Cancer Inst</source>
<year>2000</year>; <volume>92</volume>: <fpage>1881</fpage>&#x02013;<lpage>8</lpage>. .<pub-id pub-id-type="pmid">11106679</pub-id></mixed-citation></ref><ref id="pone.0183321.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>You</surname><given-names>WC</given-names></name>, <name><surname>Brown</surname><given-names>LM</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>JY</given-names></name>, <name><surname>Jin</surname><given-names>ML</given-names></name>, <name><surname>Chang</surname><given-names>YS</given-names></name>, <etal>et al</etal>
<article-title>Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions</article-title>. <source>J Natl Cancer Inst</source>
<year>2006</year>; <volume>98</volume>: <fpage>974</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jnci/djj264">10.1093/jnci/djj264</ext-link></comment> .<pub-id pub-id-type="pmid">16849680</pub-id></mixed-citation></ref><ref id="pone.0183321.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>LY</given-names></name>. <article-title>Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after <italic>H</italic>. <italic>pylori</italic> eradication in China</article-title>. <source>Gastroenterol</source>
<year>2008</year>; <volume>134</volume>: <fpage>A233</fpage>.</mixed-citation></ref><ref id="pone.0183321.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Lane</surname><given-names>PW</given-names></name>. <article-title>Meta-analysis of incidence of rare events</article-title>. <source>Stat Methods Med Res</source>. <year>2013</year>; <volume>22</volume>: <fpage>117</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/0962280211432218">10.1177/0962280211432218</ext-link></comment> .<pub-id pub-id-type="pmid">22218366</pub-id></mixed-citation></ref><ref id="pone.0183321.ref054"><label>54</label><mixed-citation publication-type="journal"><article-title>The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease</article-title>. <source>JAMA</source>
<year>1984</year>; <volume>251</volume>: <fpage>351</fpage>&#x02013;<lpage>64</lpage>. .<pub-id pub-id-type="pmid">6361299</pub-id></mixed-citation></ref><ref id="pone.0183321.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Shepherd</surname><given-names>J</given-names></name>, <name><surname>Cobbe</surname><given-names>SM</given-names></name>, <name><surname>Ford</surname><given-names>I</given-names></name>, <name><surname>Isles</surname><given-names>CG</given-names></name>, <name><surname>Lorimer</surname><given-names>AR</given-names></name>, <name><surname>MacFarlane</surname><given-names>PW</given-names></name>, <etal>et al</etal>
<article-title>Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group</article-title>. <source>N Engl J Med</source>
<year>1995</year>; <volume>333</volume>:<fpage>1301</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199511163332001">10.1056/NEJM199511163332001</ext-link></comment> .<pub-id pub-id-type="pmid">7566020</pub-id></mixed-citation></ref><ref id="pone.0183321.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Raghav</surname><given-names>KP</given-names></name>, <name><surname>Mahajan</surname><given-names>S</given-names></name>, <name><surname>Yao</surname><given-names>JC</given-names></name>, <name><surname>Hobbs</surname><given-names>BP</given-names></name>, <name><surname>Berry</surname><given-names>DA</given-names></name>, <name><surname>Pentz</surname><given-names>RD</given-names></name>, <etal>et al</etal>
<article-title>From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume>: <fpage>3583</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2015.62.4148">10.1200/JCO.2015.62.4148</ext-link></comment> .<pub-id pub-id-type="pmid">26304898</pub-id></mixed-citation></ref><ref id="pone.0183321.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>van den Bogert</surname><given-names>CA</given-names></name>, <name><surname>Souverein</surname><given-names>PC</given-names></name>, <name><surname>Brekelmans</surname><given-names>CT</given-names></name>, <name><surname>Janssen</surname><given-names>SW</given-names></name>, <name><surname>van Hunnik</surname><given-names>M</given-names></name>, <name><surname>Ko&#x000eb;ter</surname><given-names>GH</given-names></name>, <etal>et al</etal>
<article-title>Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study</article-title>. <source>BMJ Open</source>
<year>2015</year>; <volume>5</volume>: <fpage>e007827</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmjopen-2015-007827">10.1136/bmjopen-2015-007827</ext-link></comment>
<pub-id pub-id-type="pmid">26152325</pub-id></mixed-citation></ref><ref id="pone.0183321.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Dwan</surname><given-names>K</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Clarke</surname><given-names>M</given-names></name>, <name><surname>Gamble</surname><given-names>C</given-names></name>, <name><surname>Higgins</surname><given-names>JP</given-names></name>, <name><surname>Sterne</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials</article-title>. <source>PLoS Med</source>
<year>2014</year>; <volume>11</volume>: <fpage>e1001666</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001666">10.1371/journal.pmed.1001666</ext-link></comment> .<pub-id pub-id-type="pmid">24959719</pub-id></mixed-citation></ref><ref id="pone.0183321.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>JJ</given-names></name>, <name><surname>Choe</surname><given-names>YH</given-names></name>, <name><surname>Kim</surname><given-names>HS</given-names></name>, <name><surname>Kim</surname><given-names>JI</given-names></name>, <name><surname>Chung</surname><given-names>IS</given-names></name>; <collab>Korean College of Helicobacter and Upper Gastrointestinal Research</collab>; <collab>Korean Association of Gastroenterology</collab>. [<article-title>Diagnosis and treatment guidelines for <italic>Helicobacter pylori</italic> infection in Korea</article-title>]. <source>Korean J Gastroenterol</source>
<year>2009</year>; <volume>54</volume>: <fpage>269</fpage>&#x02013;<lpage>78</lpage>. .<pub-id pub-id-type="pmid">19934608</pub-id></mixed-citation></ref><ref id="pone.0183321.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Asaka</surname><given-names>M</given-names></name>. [<article-title>Guidelines in the management of <italic>H</italic>. <italic>pylori</italic> infection in Japan&#x02014;2009 version</article-title>]. <source>Nihon Rinsho</source>
<year>2009</year>; <volume>67</volume>: <fpage>2227</fpage>&#x02013;<lpage>32</lpage>. .<pub-id pub-id-type="pmid">19999104</pub-id></mixed-citation></ref><ref id="pone.0183321.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Fock</surname><given-names>KM</given-names></name>, <name><surname>Katelaris</surname><given-names>P</given-names></name>, <name><surname>Sugano</surname><given-names>K</given-names></name>, <name><surname>Ang</surname><given-names>TL</given-names></name>, <name><surname>Hunt</surname><given-names>R</given-names></name>, <name><surname>Talley</surname><given-names>NJ</given-names></name>, <etal>et al</etal>
<collab>Second Asia-Pacific Conference</collab>. <article-title>Second Asia-Pacific Consensus Guidelines for <italic>Helicobacter pylori</italic> infection</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2009</year>; <volume>24</volume>: <fpage>1587</fpage>&#x02013;<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1440-1746.2009.05982.x">10.1111/j.1440-1746.2009.05982.x</ext-link></comment> .<pub-id pub-id-type="pmid">19788600</pub-id></mixed-citation></ref><ref id="pone.0183321.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>FL</given-names></name>, <name><surname>Hu</surname><given-names>PJ</given-names></name>, <name><surname>Liu</surname><given-names>WZ</given-names></name>, <name><surname>De Wang</surname><given-names>J</given-names></name>, <name><surname>Lv</surname><given-names>NH</given-names></name>, <name><surname>Xiao</surname><given-names>SD</given-names></name>, <etal>et al</etal>
<article-title>Third Chinese National Consensus Report on the management of <italic>Helicobacter pylori</italic> infection</article-title>. <source>J Dig Dis</source>
<year>2008</year>; <volume>9</volume>: <fpage>178</fpage>&#x02013;<lpage>84</lpage>. .<pub-id pub-id-type="pmid">18956598</pub-id></mixed-citation></ref><ref id="pone.0183321.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Malfertheiner</surname><given-names>P</given-names></name>, <name><surname>Megraud</surname><given-names>F</given-names></name>, <name><surname>O'Morain</surname><given-names>C</given-names></name>, <name><surname>Bazzoli</surname><given-names>F</given-names></name>, <name><surname>El-Omar</surname><given-names>E</given-names></name>, <name><surname>Graham</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Current concepts in the management of <italic>Helicobacter pylori</italic> infection: the Maastricht III Consensus Report</article-title>. <source>Gut</source>
<year>2007</year>; <volume>56</volume>: <fpage>772</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gut.2006.101634">10.1136/gut.2006.101634</ext-link></comment> .<pub-id pub-id-type="pmid">17170018</pub-id></mixed-citation></ref><ref id="pone.0183321.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>VP</given-names></name>, <name><surname>Wong</surname><given-names>BC</given-names></name>. <article-title>Gastric cancer chemoprevention: the current evidence</article-title>. <source>Gastroenterol Clin North Am</source>
<year>2013</year>; <volume>42</volume>: <fpage>299</fpage>&#x02013;<lpage>316</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gtc.2013.02.001">10.1016/j.gtc.2013.02.001</ext-link></comment> .<pub-id pub-id-type="pmid">23639642</pub-id></mixed-citation></ref><ref id="pone.0183321.ref065"><label>65</label><mixed-citation publication-type="book"><name><surname>Ichinose</surname><given-names>M</given-names></name>, <name><surname>Yahagi</surname><given-names>N</given-names></name>, <name><surname>Oka</surname><given-names>M</given-names></name>, <name><surname>Ikeda</surname><given-names>H</given-names></name>, <name><surname>Miki</surname><given-names>K</given-names></name>, <name><surname>Omata</surname><given-names>M</given-names></name>. <chapter-title>Screening for gastric cancer in Japan</chapter-title> In: <name><surname>Wu</surname><given-names>GY</given-names></name>, <name><surname>Aziz</surname><given-names>K</given-names></name>, eds. <source>Cancer screening for common malignancies</source>. <publisher-loc>Totowa, New Jersey</publisher-loc>: <publisher-name>Humana Press</publisher-name>, <year>2001</year><fpage>87</fpage>&#x02013;<lpage>102</lpage>.</mixed-citation></ref><ref id="pone.0183321.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Asaka</surname><given-names>M</given-names></name>, <name><surname>Kato</surname><given-names>M</given-names></name>, <name><surname>Graham</surname><given-names>DY</given-names></name>. <article-title>Strategy for eliminating gastric cancer in Japan</article-title>. <source>Helicobacter</source>
<year>2010</year>; <volume>15</volume>: <fpage>486</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1523-5378.2010.00799.x">10.1111/j.1523-5378.2010.00799.x</ext-link></comment> .<pub-id pub-id-type="pmid">21073603</pub-id></mixed-citation></ref></ref-list></back></article>